- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.05. | CHMP endorses Roche's breast cancer therapy for administration out of clinical settings | ||
| 01.05. | Er-Kim to distribute Puma's Nerlynx in Central Asian, Eastern European countries | ||
| 30.04. | Abeona announces FDA approval for cell-based gene therapy for RDEB patients | ||
| 29.04. | EMA grants orphan drug status to Purespring's IgA nephropathy treatment | ||
| 28.04. | Apnimed acquires rights to sleep apnoea treatment from Desitin Arzneimittel | ||
| 25.04. | Tempus AI, AstraZeneca, and Pathos AI join forces on cancer care | ||
| 24.04. | NICE issues final guidance endorsing Pharming's APDS therapy | ||
| 23.04. | Ensem Therapeutics' application for ETX-636 secures FDA clearance | ||
| 22.04. | Viatris files applications in Japan for approval of Effexor to treat GAD | ||
| 21.04. | US FDA clears Calidi's CLD-201 for clinical development in solid tumours | ||
| 17.04. | Glycomine secures $115m funding for Phase IIb trial of rare disease drug | ||
| 16.04. | Norgine agrees to acquire Theravia | ||
| 15.04. | INmune Bio, CGT Catapult to set up manufacturing for cell therapy platforms | ||
| 14.04. | Nona Biosciences and Atossa team up to discover breast cancer therapies | ||
| 11.04. | Imbria secures $57.5m to advance ninerafaxstat through Phase IIb nHCM trial | ||
| 10.04. | Renovaro closes merger transaction with BioSymetrics | ||
| 09.04. | France 2030 funds 4MB's knee osteoarthritis drug trial | ||
| 08.04. | ALX Oncology's ALX2004 gains FDA IND clearance to treat solid tumours | ||
| 07.04. | FDA grants breakthrough therapy status for Amgen's Uplizna to treat IgG4-RD | ||
| 04.04. | FDA clears Epicrispr's application for FSHD treatment | ||
| 03.04. | FDA grants fast track status to Biogen's BIIB080 for Alzheimer's | ||
| 02.04. | EC grants orphan designation for Pharvaris' deucrictibant drug | ||
| 01.04. | Japan's MHLW authorises Regeneron and Sanofi's Dupixent for COPD | ||
| 28.03. | BridgeBio's Beyonttra gains approval in Japan for ATTR-CM treatment | ||
| 27.03. | US FDA approves Exelixis' Cabometyx for advanced neuroendocrine tumours |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .